ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2428

Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation

Anne E Tebo1, Thomas Haven2, Aimee O. Hersh3 and Eyal Muscal4, 1Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, 2Department of Pathology, University of Utah, ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT, 3Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, 4Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoimmune diseases, Biomarkers, neurologic involvement and pediatrics

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Pediatric Rheumatology – Pathogenesis and Genetics - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Antibodies directed against N-methyl-D-aspartate type glutamate receptor (NMDAR), voltage-gated potassium channel (VGKC) or glutamic acid decarboxylase (GAD65) are frequently associated with autoimmune encephalitis (AE) in pediatric patients. Yet, the full repertoire of the autoantibody diversity in children remains poorly defined.

Methods:  Eighty-eight consecutive patient samples (59 sera and 29 CSF) received at ARUP Laboratories from Intermountain Healthcare’s Primary Children’s Medical Center, Salt Lake City, Utah and Texas Children’s Hospital, Houston, Texas for evaluation for NMDAR (cell based assays, CBA), VGKC (radioimmunoprecipitation), or GAD65 (enzyme immunoassay) antibodies were identified over a period of 12 months. Residual volume of patient samples were evaluated on a research basis by indirect immunofluorescence technique (IIFT) using cerebellum (monkey and rat), intestine (monkey), peripheral nerve and pancreas tissue sections for neuronal nuclear, Purkinje cell cytoplasmic, myelin, non-medullated and astrocyte autoantibodies (PNS Mosaic IFFT), and an CBA for Delta notch-like epidermal growth factor-related receptor (DNER). In addition, the AE mosaic IIFT with hippocampus (rat) tissue and CBA to detect antibodies to NMDAR, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), gamma amino butyric acid type B receptor (GABAbR), leucine-rich glioma inactivated 1 (LGI1), contactin associated protein-2 (CASPR-2), dipeptidyl-peptidase-like protein-6 (DPPX-6), and glycine receptor (GlyR) was utilized. This study was conducted in accordance with a University of Utah Institutional Review Board approved protocol and in compliance with ARUP policies.

Results:  Samples were received from 60 unique patients including 32 females (median age 11.8; range 0-19 years) and 28 males (median age 9.0; range 0-18 years). Antibodies were detected in 30/60 patients (50%); 23 with single antibodies and 7 subjects with 2 or more antibodies. NMDAR antibody was the most prevalent (n=15) followed by GAD65 (n=7), VGKC (n=6), non-medullated (n=4), Purkinje cell (n=3), myelin (n=3), and astrocyte (n=1) antibodies. Of the 28 patients with paired serum and CSF, 16 possessed autoantibodies; 8 NMDAR-positive (7 seropositive, 8 CSF positive), and 5 GAD65- and 4 VGKC-seropositive only. Eighty percent (24/30) of the antibody-positive patients in our cohort had NMDAR, GAD65 and/or VGKC antibodies; however, a sizable number of patients possessed autoantibodies not typically associated with pediatric AE.

Conclusion:   Overall, NMDAR, GAD and VGKC autoantibodies were the most prevalent antibodies detected in this two center pediatric cohort of samples analyzed at a large referral lab. Prevalence of these antibodies approximates previous reports in the pediatric literature. Additional autoantibodies targeting diverse proteins and associated neurologic functions were also detected demonstrating a need for the validation of additional markers for pediatric AE such as the Purkinje cell and nerve (i.e. non-medullated nerve and myelin) autoantibodies detected in this cohort of patients.


Disclosure: A. E. Tebo, None; T. Haven, None; A. O. Hersh, None; E. Muscal, None.

To cite this abstract in AMA style:

Tebo AE, Haven T, Hersh AO, Muscal E. Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/autoantibody-diversity-in-pediatric-patients-undergoing-evaluation-for-autoimmune-encephalitis-a-retrospective-investigation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibody-diversity-in-pediatric-patients-undergoing-evaluation-for-autoimmune-encephalitis-a-retrospective-investigation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology